Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Analysis of systemic and pulmonary vascular responses to PACAP and VIP: role of adrenal catecholamines

Analysis of systemic and pulmonary vascular responses to PACAP and VIP: role of adrenal... Minkes, Robert K., Timothy J. McMahon, Todd R. Higuera, William A. Murphy, David H. Coy, Philip J. Kadowitz. Analysis of systemic pulmonary vascular s VIP: role of catecholamines. Am. J. Physiol. 263 (Heart Circ. Physiol. 32): H1659-H1669, 1992.-Systemic pulmonary vascular s to pituitary adenylate cyclase-activating polypeptide (), a novel peptide with 68% sequence homology to vasoactive intestinal peptide (VIP), were investigated in the anesthetized cat. Intravenous injections of in doses of 0.1-3.0 nmol/kg produced decreases in arterial pressure (AP) at low doses biphasic changes (decreases followed by increases) at higher doses, which were accompanied by increases in central venous pressure (CVP) cardiac output (CO), decreases biphasic changes in systemic vascular resistance (SVR). In contrast, VIP in doses of 0.1-3.0 nmol/kg produced only dose-dependent decreases in AP SVR produced little change in CVP CO. produced increased pulmonary arterial pressure (PAP), left atria1 pressure (LAP), increases in pulmonary vascular resistance (PVR). increased heart rate (HR) right ventricular contractile force (RVCF), while VIP had no effect. Increases in AP SVR in were changed to decreases following the administration of phentolamine or after ectomy. Under constant flow conditions, VIP produced dose-dependent decreases in lobar arterial pressure when tone was elevated, with being http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png AJP - Heart and Circulatory Physiology The American Physiological Society

Analysis of systemic and pulmonary vascular responses to PACAP and VIP: role of adrenal catecholamines

Loading next page...
 
/lp/the-american-physiological-society/analysis-of-systemic-and-pulmonary-vascular-responses-to-pacap-and-vip-KXxsgD0BIS

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
The American Physiological Society
Copyright
Copyright © 1992 the American Physiological Society
ISSN
0363-6135
eISSN
1522-1539
Publisher site
See Article on Publisher Site

Abstract

Minkes, Robert K., Timothy J. McMahon, Todd R. Higuera, William A. Murphy, David H. Coy, Philip J. Kadowitz. Analysis of systemic pulmonary vascular s VIP: role of catecholamines. Am. J. Physiol. 263 (Heart Circ. Physiol. 32): H1659-H1669, 1992.-Systemic pulmonary vascular s to pituitary adenylate cyclase-activating polypeptide (), a novel peptide with 68% sequence homology to vasoactive intestinal peptide (VIP), were investigated in the anesthetized cat. Intravenous injections of in doses of 0.1-3.0 nmol/kg produced decreases in arterial pressure (AP) at low doses biphasic changes (decreases followed by increases) at higher doses, which were accompanied by increases in central venous pressure (CVP) cardiac output (CO), decreases biphasic changes in systemic vascular resistance (SVR). In contrast, VIP in doses of 0.1-3.0 nmol/kg produced only dose-dependent decreases in AP SVR produced little change in CVP CO. produced increased pulmonary arterial pressure (PAP), left atria1 pressure (LAP), increases in pulmonary vascular resistance (PVR). increased heart rate (HR) right ventricular contractile force (RVCF), while VIP had no effect. Increases in AP SVR in were changed to decreases following the administration of phentolamine or after ectomy. Under constant flow conditions, VIP produced dose-dependent decreases in lobar arterial pressure when tone was elevated, with being

Journal

AJP - Heart and Circulatory PhysiologyThe American Physiological Society

Published: Dec 1, 1992

There are no references for this article.